Investing in biotechnology, pharmaceutical, medical technology and telemedicine stocks has reached a new level of interest for investors, fueled by groundbreaking innovations reshaping healthcare and technology. Learn how AI is playing a key role. Get the latest news and articles and check out the free stock directory at Investorideas.com.
Featured Biotech Stock
(NASDAQ: AEMD) is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Biotech News
Biotech Stock Nektar Therapeutics (Nasdaq: NKTR) Makes Top Gainer List on News of REZOLVE-AD Study |
Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026 |
Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) Announces Publication of Hemopurifier Preclinical Data |
Actinium's (NYSE American: ATNM) High-Stakes Sprint: Betting Big on the Explosive Global Cancer Radiotherapy Boom |
Co-Diagnostics, Inc. (Nasdaq: CODX) Leads Nasdaq Top Gainers on new Saudi-based CoMira Diagnostics joint venture |
Pharma Stock SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) Makes Nasdaq Top Gainer on News of Commercial Sales and Fulfillment of First Orders for Arbli |
Biotech Stock Artiva Biotherapeutics (Nasdaq: ARTV) Soars on News FDA has granted Fast Track Designation to AlloNK |
Rani Therapeutics (Nasdaq: RANI) Makes Nasdaq Top Gainer on $1.085 Billion Pharma Collaboration News |
Gene Therapy Stock Genprex, Inc. (NASDAQ: GNPX) Makes Nasdaq Top Gainers List on News of Positive Preclinical Data on the Use of Reqorsa |
Biotech and Medical Tech Stocks to Watch - Big Moves Following Clinical Trial News |
Other Ideas - Guest Posts / Sponsored Content
Learn how to be published on our site: Buy a guest post on Investorideas.com
Biotech Stock ETF's
|
First Trust NYSE Arca Biotech ETF
(NYSEArca: FBT) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified. |
|
iShares US Healthcare (NYSEArca:
IYH) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified. |
|
iShares US Healthcare Providers
(NYSEArca: IHF) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified. |
|
iShares US Medical Devices
(NYSEArca: IHI) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified. |
|
iShares Nasdaq Biotechnology
(NasdaqGIDS: IBB) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified. |
|
Market Vectors Biotech ETF (NYSE
MKT: BBH) Seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified. |
|
PowerShares Dynamic Biotech &
Genome ETF (NYSEArca: PBE) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified. |
Biotech News from Newsfile
Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection |
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update |
Envoy Medical Announces Pricing of Up to $78.0 Million Upsized Public Offering |
NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production |
Neural Portfolio Company Hanf.com Reports Strong Fiscal 2025 Results with 58% Revenue Growth and Positive Normalized Operating Income |